Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Male
Incontinence Post-robotic Prostatectomy
Male
Incontinence Post-robotic Prostatectomy
Trial Information
Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy
Inclusion Criteria:
- Patients that have been diagnosed with prostate cancer and will undergo treatment for
the disease as part of standard clinical care
- Patients that have multiple pad use a few days after standard of care catheter
removal
Exclusion Criteria:
- Contra-indication to Solifenacin
- Narrow angle glaucoma
- Hepatic impairment
- Renal impairment
- CYP3A4 inhibitors (e.g. Ketoconazole)
- Gastric Retention (delayed or slow emptying of the stomach)
- Lives in a different country
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Time to Continence
Outcome Time Frame:
12 months
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
2007-5720-2
NCT ID:
NCT01215721
Start Date:
October 2010
Completion Date:
September 2013
Related Keywords:
- Incontinence Post-robotic Prostatectomy
- Incontinence
- Robotic Prostatectomy
- Prostate Cancer
- Urinary Incontinence
Name | Location |
|---|---|
| University of California, Irvine Medical Center | Orange, California 92868 |
